Profilo
Ray Lockard is currently Chief Manufacturing & Quality Officer at TScan Therapeutics, Inc., starting in 2026.
Formerly, Mr. Lockard was Executive Director-CMC, QA & External Quality at Ultragenyx Pharmaceutical, Inc. from 2020 to 2021 and Head-Site Quality at Novartis Gene Therapies, Inc. from 2019 to 2020.
Education includes an undergraduate degree from Hampden-Sydney College and an MBA from Kenan-Flagler Business School.
Posizioni attive di Ray Lockard
| Società | Posizione | Inizio |
|---|---|---|
| TSCAN THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2024 |
Precedenti posizioni note di Ray Lockard
| Società | Posizione | Fine |
|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Corporate Officer/Principal | 01/12/2021 |
| AVEXIS INC | Corporate Officer/Principal | 01/10/2020 |
Formazione di Ray Lockard
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 5 |
|---|---|
Ultragenyx Pharmaceutical, Inc.
Ultragenyx Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel products for the treatment of serious rare and ultra-rare genetic diseases | Health Technology |
Hampden-Sydney College
Hampden-Sydney College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kenan-Flagler Business School
Kenan-Flagler Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Gene Therapies, Inc.
Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Operates as a clinical-stage gene therapy company | Health Technology |
TScan Therapeutics, Inc.
TScan Therapeutics, Inc. BiotechnologyHealth Technology Develops T-cell therapies for cancer patients | Health Technology |
















